

# Drug Resistance Patterns of Acinetobacter Baumannii Infection in Intensive Care Unit of a Tertiary Care Hospital of Sindh

Inayatullah Memon<sup>1</sup>, Attaullah Memon<sup>2</sup> and Attiya Memon<sup>1</sup>

## ABSTRACT

**Objectives:** The present study evaluated the drug resistance patterns of *Acinetobacter baumannii* infection in Intensive care unit of a tertiary care hospital of Sindh.

**Study Design:** Cross sectional study

**Place and Duration of Study:** This study was conducted at Indus Medical College Hospital, Tando Muhammad Khan, Sindh, Pakistan from June 2015 to November 2016.

**Materials and Methods:** Of 521 samples, the *A. baumannii* were detected in 95 samples. API 20 E kit (Biomérieux, USA) was used for the bacterial identification. Antibiotic susceptibility was checked by the Kirby-Bauer disk diffusion method (Oxoid, UK) and E-test (AB BIODISK, Sweden). E-test was used for the intermediate drug sensitivity or resistance was noted. Data was analyzed on GraphPad Prism software.

**Results:** Of 521 samples inoculated the *A. baumannii* was isolated from the 95 samples, this yielded a frequency of 18.23%. Drug resistance was noted for the amikacin, minocycline, tazocin, imipenem, meropenem, ceftazidim, cefixime, ceftriaxone and cefepime. *A. baumannii* showed no resistance for the Colistin.

**Conclusion:** The present study shows drug resistant *A. baumannii* in intensive care units of a tertiary care hospital. *A. baumannii* shows drug resistance against the aminoglycosides, tetracyclines and cephalosporins.

**Key Words:** *Acinetobacter baumannii*, Drug resistance, Intensive care units Sindh

**Citation of article:** Memon I, Memon A, Memon A. Drug Resistance Patterns of *Acinetobacter Baumannii* Infection in Intensive Care Unit of a Tertiary Care Hospital of Sindh. Med Forum 2017;28(4):100-103.

## INTRODUCTION

*Acinetobacter baumannii* (*A. baumannii*) is a notorious microorganism known to cause infections in the intensive care units. It is a common cause of nosocomial and community infections. It is a gram negative obligate aerobic bacterium. *A. baumannii* is catalase positive, non-motile, non-fermenting and peroxidase negative cocco-bacilli. Approximately >30 species are recognized.<sup>1,2</sup> Route of transmission includes the burn and skin wounds, mucosal tears, urinary catheters and intravenous catheters.<sup>2,3</sup> Nosocomial infection by *A. baumannii* are contracted by fomites, resuscitation devices, infusion pumps, contaminated instruments, etc.<sup>4</sup> Worldwide nosocomial infections by *A. baumannii* now account for most of the morbidities and mortalities particularly in the intensive care unit settings.<sup>5,6</sup> *A. baumannii* may cause community acquired infections.<sup>1,5</sup>

*A. baumannii* may cause bacteremia, septicemia, urinary infections, infective endocarditis, and respiratory infections.<sup>7</sup> *A. baumannii* is specially geared with methods of virulence, such as the adhesions to mucosa, epithelia, skin colonization, iron chelation, and bio-film formation. Gelatinase and protease enzymes are also produced by the *A. baumannii*. These methods of virulence are essential for the pathogenicity of *A. baumannii*.<sup>8</sup> Iron is essential for the growth of *A. baumannii* similar to many of other microorganisms.<sup>5</sup> *A. baumannii* is responsible for life threatening serious infections usually ventilator associated pneumonia, skin and soft tissue infections, post surgical meningitis, etc.<sup>9,10</sup> Moreover, *A. baumannii* has primarily emerged as a nosocomial bacterium. Primary infections occur in the immunocompromised patients in hospital intensive care units (ICUs).<sup>11,12</sup> *A. baumannii* spread occurs from intensive care units to the medical wards by direct person to person contact of an infected patient, a staff member, a nurse and fomites. Such type bacterial contamination may result in the sequential infection outbreaks, ICU dispersal, endemicity and clonal spread between hospitals and cities.<sup>13,14</sup> The present study was conducted to evaluate the frequency and drug sensitivity and resistance patterns of *A. baumannii* infection at our tertiary care hospital of Sindh.

<sup>1</sup>: Department of Pathology / Anaesthesiology<sup>2</sup>, Indus Medical Colleges, T. M. Khan, Sindh, Pakistan

Correspondence: Dr. Inayatullah Memon, Assistant Professor of Pathology, Indus Medical Colleges, T. M. Khan, Sindh, Pakistan  
Contact No: 0300-9371766  
Email: memon.inayat@gmail.com

## MATERIALS AND METHODS

The present cross sectional study was conducted at the Indus Medical College Hospital, Tando Muhammad Khan, Sindh, Pakistan from June 2015 to November 2016. The hospital is equipped with modern facilities of Pathology laboratory. State of the Art facility of intensive care unit and blood testing are matchless. Our hospital caters both indoor and outdoor patients including surgical and medical emergencies. Pathology laboratory has blood sampling facilities and collection of bacterial isolates from ICU patients. The patients proved *A. baumannii* infection after blood culture was included in the study protocol. Samples accepted for the inoculation included the blood, urine, pus, intravenous catheters, urinary catheters, or any other body fluid. The samples were inoculated on the blood culture media. Of 721 samples, the *A. baumannii* were isolated from 95 blood samples. Criteria of Clinical and Laboratory Standards Institute (CLSI) were followed for the sample processing, isolation and identification of microorganism and drug sensitivity. Samples were inoculated on the MacConkey and Blood agar media (Oxoid Ltd., Cambridge, UK) for the bacterial growth. Bacterial isolates were stained with Gram's staining and identified by standard microbiological methods. API 20 E kit (Biomerieux, USA) was used for the purpose of bacterial isolate identification.<sup>15</sup> Bacterial drug sensitivity and resistance was run on the Phoenix BD Automated Microbiology system. MIC (minimum inhibitory concentration) of antibiotics was used on the Phoenix system and included; imipenem, meropenem, cefixime, cefepime, ceftazidim, piperacillin/tazobactam and amikacin. Antibiotic susceptibility was checked by the Kirby-Bauer disk diffusion method (Oxoid, UK) and E-test (AB BIODISK, Sweden). E-test was used for the intermediate drug sensitivity or resistance was noted. All methods were in accordance to the CLSI criteria.<sup>16</sup> Reference bacterial strains were used to ensure the quality control. Written informed consent of patients or attendants was taken. Prior ethical permission was taken from the institute's research ethics committee. All the data kept in pre structured proforma. Confidentiality of personal data of patients was ensured. Statistical analysis was performed on GraphPad Prism online Software. Continuous and categorical variables were analyzed by the Student's t - test and Chi-square test. Data was analyzed at 95% Confidence interval ( $p \leq 0.05$ ).

## RESULTS

Mean  $\pm$  SD age of study subjects was  $50.5 \pm 13.8$  years. Of 95 subjects, 53 (55.7%) were male and 42 (44.21%) were female ( $p=0.012$ ) (table I). Of 521 samples inoculated the *A. baumannii* was isolated from the 95 samples, this yielded a frequency of 18.23%. MIC concentrations were categorized as


sensitive, intermediate sensitive and resistant for E-test and Disk diffusion technique as shown in table II. *A. baumannii* showed no resistance for the Colistin. Drug resistance was shown for the amikacin, minocycline, tazocin, imipenem, meropenem, ceftazidim, cefixime, ceftriaxone and cefepime. Bar graph 1 shows the drug sensitivity, intermediate sensitivity and resistance patterns.

**Table No. I: Demographic characteristics of study subjects (n=95)**

	No.	%
ICU	100	100
Male	53	55.7
Female	42	44.21
Blood	95	100
Sputum	33	34.73
Urine	78	82.10
Catheters	67	70.52
Pleural fluids	09	9.47
Secretions	37	38.94

**Table No.2: Drug sensitivity patterns of *A. baumannii* by E-test and disk diffusion technique (n=95)**

Antibiotics	Sensitive	Intermediate	Resistant
Amikacin	23(24.2%)	0(0%)	72(75.7%)
Minocycline	16(16.84%)	1(1.05%)	78(82.1%)
Tazocin	92(96.84%)	3(3.15%)	0(0%)
Imipenem	93(97.89%)	2(2.1%)	0(0%)
Meropenem	90(94.73%)	3(3.15%)	2(2.1%)
Ceftazidim	78(82.1%)	16(16.84%)	1(1.05%)
Cefixime	80(84.21%)	9(9.47%)	6(6.31%)
Ceftriaxone	76(80%)	12(12.63%)	7(7.36%)
Cefepime	92(96.84%)	3(3.15%)	0(0%)
Colistin	95(100%)	0(0%)	0(0%)



**Graph No.1: Drug sensitivity and resistance patterns**

## DISCUSSION

*Acinetobacter baumannii* has emerged globally as a target pathogen of critically sick patients in intensive care units.<sup>17</sup> The present study is the first of its design conducted at intensive care unit of Indus Medical College Hospital. We are the first reporting on the frequency and drug susceptibility patterns of *A.*

baumanii in the ICU patients at our tertiary care hospital. Of 521 samples inoculated the *A.baumannii* was isolated from the 95 samples, this yielded a frequency of 18.23%. *A.baumannii* showed no resistance for the Colistin. Drug resistance was noted for the amikacin, minocycline, tazocin, imipenem, meropenem, ceftazidim, cefixime, ceftriaxone and cefepime. The findings are in agreement with previous studies.<sup>17,18</sup> The frequency of 18.23% is comparable finding to a previous report of 16% per patient-year.<sup>19</sup> However, the true frequency and prevalence of *A. baumannii* is not known in Pakistan. The findings of present study are in consistent with previous reports.<sup>20,21</sup> Previous studies<sup>17,22,23</sup> have reported *A baumannii* bacteremia in 82.2% and 15.8% in children in intensive care unit. These findings are in keeping with the present study. The meropenem and imipenem resistance was found in 2.1% which is in agreement with previous studies,<sup>24,25</sup> they reported the *A. baumannii* have acquired carbapenems resistance. The findings are in support to the present study. Drug resistance was observed against the amikacin and Cephalosporins in present study which is in agreement with previous studies.<sup>24-26</sup> A recent study<sup>26</sup> showed grave observations on the resistance patterns of *A.baumannii*. This previous study<sup>26</sup> showed severe drug resistance against the imipenem, meropenem, cefepime and gentamicin. In present study *A. baumannii* showed drug resistance against meropenem but not the imipenem. The drug resistance of *A. baumannii* against imipenem and meropenem of present study is very low and inconsistent to a previous study<sup>27</sup> which reported high drug resistance *A. baumannii* against imipenem and meropenem. The same study<sup>27</sup> reported high drug resistance against ceftazidim, cefepime, amikacin, and tazocin. The finding of cephalosporin and amikacin of present study is in agreement with above study. A previous study<sup>28</sup> reported 100% susceptibility of *A. baumannii* to imipenem; the finding is consistent to present study (table II). They reported approximately 69% drug resistance for the ceftazidim and gentamicin<sup>28</sup> which is low compared to the present study. In the present study, the *A.baumannii* susceptible to imipenem, amikacin and ceftazidim were noted in was noted as 24%, 82% and 97% respectively. This shows high drug resistance against the aminoglycosides and Cephalosporins. Another previous study<sup>29</sup> noted 38.3% imipenem drug resistance which is very high and inconsistent to present study. A recent study<sup>30</sup> has reported high drug resistant strains of *A.baumannii* against the aminoglycosides and cephalosporins, the findings of present study are in support with above report. However, they<sup>30</sup> reported *A. baumannii* strain exhibited approximately 70% resistance against imipenem and meropenem, this finding is in contrast to present study. However, it is worth to report that the present study has reported on

very important health problem of drug resistant *A. baumannii* which needs to be visited from time to time as new drug resistant strains always emerge suddenly, this increases the mortality rates in the intensive care units. In conclusion, drug resistant *A. baumannii* infections are noted in intensive care units and emergence of multi drug resistance and extensively drug resistant strains is a major risk for patients. A restrictive use of antimicrobials is recommended with prior culture and sensitivity testing to prevent further drug resistance.

## CONCLUSION

The present study shows drug resistant *A. baumannii* in intensive care units of a tertiary care hospital. *A. baumannii* shows drug resistance against the aminoglycosides, tetracyclines and cephalosporins. *A. baumannii* needs further studies for drug susceptibility patterns to estimate the magnitude of problem. Antibiotic use should be strictly controlled and drugs be prescribed only after culture and sensitivity results are available

**Conflict of Interest:** The study has no conflict of interest to declare by any author.

## REFERENCES

1. Lazureanu V, Poroşnicu M, Gandac C, Moşil T, Badiţoiu L, Laza R, et al. Infection with *Acinetobacter baumannii* in an intensive care unit in the Western part of Romania. *BMC Infect Dis* 2016;16(Suppl 1):95:24-8.
2. Al-Anazi KA, Al-Jasser AM. Infections caused by *Acinetobacter baumannii* in recipients of hematopoietic stem cell transplantation. *Frontiers Oncolog* 2014;186.
3. Obeidat N, Jawdat F, Al-Bakri AG, Shehabi AA. Major biologic characteristics of *Acinetobacter baumannii* isolates from hospital environmental and patients' respiratory tract sources. *Am J Infect Control* 2014;42(4):401-4.
4. Uwingabiye J, Mohammed Frikh M, Lemnouer A, Bssaibis F, Belefquih B, Maleb A, et al. *Acinetobacter* infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care units versus other hospital units. *Pan Afr Med J* 2016; 23: 191.
5. Gentile V, Frangipani E, Bonchi C, Minandri F, Runci F, Visca P. Iron and *Acinetobacter baumannii* Biofilm Formation. *Pathogens* 2014;3: 704-19.
6. Antunes LC, Visca P, Towner KJ. *Acinetobacter baumannii*: Evolution of a global pathogen. *Pathog Dis* 2014;71:292-301.
7. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 2007;5: 939-51.
8. Eveillard M, Kempf M, Belmonte O, Pailhoriès H, Joly-Guillou ML. Reservoirs of *Acinetobacter baumannii* outside the hospital and potential involvement in emerging human community-acquired infections. *Int J Infect Dis* 2013; 17: e802-

- e805.
9. Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by *Acinetobacter baumannii*: Involvement of a novel chaperone-usher pili assembly system. *Microbiol* 2003;149:3473–84.
  10. Ansari SH, Shamsi TS, Ashraf M, Borhany M, Farzana T, Khan MT, et al. Molecular epidemiology of  $\beta$ -thalassemia in Pakistan: far reaching implications. *Int J Mol Epidemiol Genet* 2011; 2(4):403-8.
  11. Lin MF, Lan CY. Antimicrobial resistance in *Acinetobacterbaumannii*: From bench to bedside. *World J Clin Cases* 2014;2(12):787-814.
  12. Halachev MR, Chan JZ, Constantinidou CI, Cumley N, Bradley C, Smith-Banks M, et al. Genomic epidemiology of a protracted hospital outbreak caused by multidrug-resistant *Acinetobacter baumannii* in Birmingham, England. *Genome Med* 2014; 6(11):70.
  13. Ahmed S, Saleem M, Modell B, Petrou M. Screening extended families for genetic hemoglobin disorders in Pakistan. *N Engl J Med* 2010; 347: 1162-68.
  14. Lin MF, Lan CY. Antimicrobial resistance in *Acinetobacterbaumannii*: From bench to bedside. *World J Clin Cases* 2014;2(12):787-814.
  15. Koneman EW, Allen SD, Janda WM, Schereckenberger PC, Winn JWC. *Color Atlas and Text Book of Diagnostic Microbiology*, 5th ed. Philadelphia- New York: Lippincott; 1997.p.211-302.
  16. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo PN. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2007; 51(10): 3471-384.
  17. Yadegarinia D, AbedySh, Gachkar L, RahmatiRoodsari S. Prevalence and drug resistance of *Acinetobacterbaumannii* in ICU of teaching hospital. *J Appl Environ BiolSci* 2013;3(9):22-7.
  18. Al-Marzoqi AH, Shemmran AR, Al-Hindi ZS. Bacterial and viral infections associated with thalassemia patients in Hillah City. *Iraqi Acad Sci J* 2008; 1:7-15.
  19. Wang SC, Lin KH, Chern JPS, Lu MY, Jou ST, Lin DT, et al. Severe Bacterial Infection in Transfusion-Dependent Patients with Thalassemia Major. *Clin Infect Dis* 2003; 37:984–8.
  20. Lee HW, Koh YM, Kim J, Lee JC, Seol SY, Cho, DT, et al. Capacity of multidrug-resistant clinical isolates of *Acinetobacter baumannii* to form biofilm and adhere to epithelial cell surfaces. *Clin. Microbiol. Infect* 2008;14:49–54.
  21. Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by *Acinetobacter baumannii*: Involvement of a novel chaperone-usher pili assembly system. *Microbiol* 2003; 149:3473–84.
  22. Casal M, Rodríguez F, Johnson B, Garduno E, Tubau F, deLejarazu RO, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-nonsusceptible *Acinetobacter* spp. *J Antimicrob Chemother* 2009;64(1):69-72.
  23. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of *Acinetobacterbaumannii* isolates from Korea. *J Antimicrob Chemother* 2007;60(5):1-8.
  24. Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and Distribution of bla<sub>oxa</sub> Genes among *Acinetobacter* spp. Isolated from patients at Tehran Hospitals. *Jpn J infects Dis* 2008;61:274-8.
  25. Ekrami A, Kalantar E. Bacterial infections in burn patients at a burn hospital in Iran. *Ind J Med Res* 2007;126:541-4.
  26. Yadegarynia D, Khalili Azad M, Gachkar L, RahmatiRoodsari S, Arab-Mazar Z. Drug Resistance of *Acinetobacter* in Selected Hospitals. *Novel Biomed* 2015;3(3):103-10.
  27. Bayram A, Balci I. Patterns of antimicrobial resistance in a surgical intensive care unit of a university hospital in Turkey. *BMC Infect Dis* 2006;25(6):155.
  28. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibigrams of multidrug – Resistant clinical *Acinetobacterbaumannii* promising therapeutic options for treatment of infection with colistin – Resistant strains. *Clin Infect Dis* 2007;45(5):594-8.
  29. Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E. An outbreak of multidrug Resistant *Acinetobacterbaumannii calcoaceticus* complex infection in the US military Health care system Associated with military operation in Iraq. *Clin Infect Dis* 2007;44(12):1577-84.
  30. Petersen K, Riddle MS, Danko JR, Blazes DL, Hayden R, Tasker SA et al. Trauma-related infections in Battlefield casualties From Iraq. *Ann surg. Ann Surg* 2007;245(5):803-11.